Aktiesnakken — Juli 2012
-
Novartis bättre än väntat
Det schweiziska läkemedelsbolaget Novartis redovisar ett resultat efter skatt på 3,4 miljarder dollar för det andra kvartalet 2012.
Dagens industri (www.di.se)
-
-
det plejer vist at komme tidligt om morgenen?
-
godmorgen.. fandt lige ud af at jeg købte US papirer for 19000 kr for leden dag og måtte slippe med 500 kr i kurtage damn Jyske bank er blevet dyr at handle igennem
-
så er det mig der husker forkert, tak turin
-
for mit vedkommende bliver det ikke igennem JB mere
-
er der nogen der har hørt om at 35000 skibe skal retrofittes for at overholde nogle nye krav om ballastvand
-
og der vist ligger nogle selskaber der kunne være interessante som følge heraf, Danaher er en af dem.
-
det kan være en virksomhed at putte på skemaet over interessante muligheder for 2012-13
-
men min research syncs bare at de er mere life science end vandrensende?
-
record revenues of $16.1 billion with core revenue growth of 7%.
r&D spending exceeded $1 billion for the first time in Danaher’s history.
Free cash flow of $2.4 billion with a free cash flow to net income conversion ratio of 124%, representing the 20th consecutive year in which free cash flow exceeded net income.
Deployed a record $7.5 billion of capital to acquire 14 new companies, including Beckman Coulter, across all five operating segments. -
det var så Danaher. som ganske rigtigt har noget vand rensende under opsejling
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind